Business Intelligence

Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.

Medicare Money dollar payment reimbursement

Humana buys stake in Healthpilot to expand Medicare Advantage portfolio

Healthpilot will remain an independent, payer-agnostic company despite Humana’s minority stake.

Thumbnail

Nationwide IT outage leaves hospitals without EHRs

Many hospitals that use Epic were unable to access services, forcing them to operate on pen-and-paper and cancel non-emergency care delivery. The disruption was caused by an error with security vendor CrowdStrike.

mayo clinic platform

Industry Watcher’s Digest

Buzzworthy developments of the past few days: Mayo Clinic leads the league in AI readiness 

healthcare money economics dollar stethoscope acquire merger

Private equity firms back less than 4% of healthcare providers, report finds

According to an analysis from PitchBook, providers backed by private equity make up only 3.3% of the total market by revenue.

Hospital

Industry Watcher’s Digest

Buzzworthy developments of the past few days. The Sam Altman-Arianna Huffington ‘AI health coach’ has attracted detractors ... 

Department of Justice DOJ

DOJ investigating Steward Health Care over ties to foreign government

Citing two sources familiar with the matter, journalists at CBS News said the health system is suspected of violating the Foreign Corrupt Practices Act. No charges have been filed.

'Well-resourced and innovation-focused hospitals should mentor and provide technical support to underfunded or smaller hospitals.'

How to mitigate institutional inequities involving AI

When it comes to adopting healthcare AI, large, well-off hospitals are likely to frequently homer while smaller, struggling institutions go down looking. (Baseball analogy in honor of tonight’s Midsummer Classic.) 

Eli Lilly

Eli Lilly purchases Morphic and its Crohn's drug portfolio for $3.2B

Morphic's new treatment for inflammatory bowel disease is in Phase II clinical trials and shows promise in improving patient outcomes. Eli Lilly will purchase the company for $57 per share in cash.